CRP and chronic kidney disease: Furthermore, a very recent secondary analysis of the CANTOS trial showed that in participants without CKD, inflammation biomarkers (CRP and IL-6) and LDL-Cholesterol all predicted major CV events while in CKD patients only inflammatory biomarkers but not LDL cholesterol predicted the same events.98 By the same token, in a double-blind, randomized, placebo-controlled phase 2 trial, IL-6 inhibition with ziltivekimab in CKD patients at high atherosclerotic risk markedly reduced biomarkers of inflammation.99